Alcon AG
SIX:ALC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
63.02
84.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Alcon AG
Alcon AG
Cost of Revenue
Alcon AG
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alcon AG
SIX:ALC
|
Cost of Revenue
-$4.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Coltene Holding AG
SIX:CLTN
|
Cost of Revenue
-CHf83.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Medartis Holding AG
SIX:MED
|
Cost of Revenue
-CHf42.9m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Ypsomed Holding AG
SIX:YPSN
|
Cost of Revenue
-CHf398.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-7%
|
|
|
IVF Hartmann Holding AG
SIX:VBSN
|
Cost of Revenue
-CHf68.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
Alcon AG
Glance View
Alcon AG, a leader in the global eye care industry, is dedicated to enhancing the quality of life for patients through innovative solutions and cutting-edge technologies. Formed in 1945, the company specializes in developing, manufacturing, and marketing surgical and vision care products that cater to a wide range of eye-related conditions. With a robust portfolio that includes advanced cataract surgery instruments, contact lenses, and dry eye treatments, Alcon has positioned itself as a formidable player in both the surgical and non-surgical segments of the market. The company's commitment to research and development ensures a steady stream of innovations, attracting a loyal customer base among healthcare professionals and patients alike. For investors, Alcon AG presents a compelling opportunity driven by its strong market presence and a favorable demographic backdrop, with an aging population increasingly in need of vision care solutions. The company has demonstrated consistent revenue growth and profitability, buoyed by strategic acquisitions and a willingness to invest in future growth areas, such as digital health and myopia management. Additionally, with a robust pipeline of products and a focus on expanding markets, Alcon is well-positioned to capitalize on the growing demand for eye care solutions. As it continues to navigate the evolving landscape of the healthcare sector, Alcon AG stands out as a promising investment for those seeking exposure to the eye care market.
See Also
What is Alcon AG's Cost of Revenue?
Cost of Revenue
-4.2B
USD
Based on the financial report for Dec 31, 2023, Alcon AG's Cost of Revenue amounts to -4.2B USD.
What is Alcon AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-3%
Over the last year, the Cost of Revenue growth was -7%. The average annual Cost of Revenue growth rates for Alcon AG have been -4% over the past three years , -3% over the past five years .
You don't have any saved screeners yet
